Development and demonstration of clinical potential for a multi-biomarker-based, low-cost, point of care, lateral flow blood test for active tuberculosis.

结核病（TB）是英国和世界范围内持续存在的健康问题。在过去的三十年里，英国的结核病发病率稳步上升，目前是欧洲疾病负担最高的国家之一。2013年，世卫组织报告说，2012年印度诊断出280万例活动性结核病病例，估计有2520万人患有推定结核病，这表明诊断“成功率”仅为1/9。该申请将资助一个由行业主导的工业研究项目，以开发一种负担得起的新型结核病诊断方法，目的是提高四个结核病负担最高的国家的诊断成功率，这些国家占全球每年发现的所有结核病病例的近一半。该项目结合了帝国理工学院伦敦（ICL）研究的创新，开发了一套强大的结核病诊断血液生物标志物，以及低成本的横向流动技术，将满足全球对活动性结核病低成本筛查工具的需求，从而实现更好的疾病治疗和遏制。

Tuberculosis (TB) is a persistent health problem in the UK and worldwide. There has been a steady increase of TB rates in the UK over the last three decades, with the disease burden now one of the highest in Europe. In 2013 the WHO reported that in India in 2012 2.8M active TB cases were diagnosed, with an estimate of 25.2M individuals with presumptive TB, suggesting a diagnosis "success rate" of only 1 in 9\. This application is to fund an industry-led, industrial research project to develop an affordable new TB diagnostic with the aim of increasing this diagnostic success rate in the four highest burden TB countries, which account for nearly half of all TB cases detected globally each year. The project combines innovation from Imperial College London (ICL) research into the development of a powerful set of TB diagnostic blood biomarkers together with low cost lateral flow technology that will address the worldwide need for a low-cost screening tool for active TB, enabling better disease treatment and containment.